David Altshuler, Vertex CSO
October 9, 2023 09:00 AM EDT
People
R&D

Ex­clu­sive: Ver­tex CSO David Alt­shuler talks non-opi­oid pain pills, AI and the myth of break­throughs

Andrew Dunn

Senior Biopharma Correspondent

Short­ly af­ter jump­ing from acad­e­mia to in­dus­try in 2015, David Alt­shuler helped an­swer an ex­is­ten­tial ques­tion for Ver­tex Phar­ma­ceu­ti­cals. The Boston biotech was rid­ing high …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times